Pathophysiology, Risk Factors, and Screening Methods for Prediabetes in Women with Polycystic Ovary Syndrome

Overview

Journal Int J Womens Health

Publisher Dove Medical Press

Specialty Gynecology & Obstetrics

Date 2016 Aug 30

PMID 27570464

Citations 5

Authors

Evgenia Gourgari

Elias Spanakis

Adrian Sandra Dobs

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is a syndrome associated with insulin resistance (IR), obesity, infertility, and increased cardiometabolic risk. This is a descriptive review of several mechanisms that can explain the IR among women with PCOS, other risk factors for the development of diabetes, and the screening methods used for the detection of glucose intolerance in women with PCOS. Few mechanisms can explain IR in women with PCOS such as obesity, insulin receptor signaling defects, and inhibition of insulin-mediated glucose uptake in adipocytes. Women with PCOS have additional risk factors for the development of glucose intolerance such as family history of diabetes, use of oral contraceptives, anovulation, and age. The Androgen Society in 2007 and the Endocrine Society in 2013 recommended using oral glucose tolerance test as a screening tool for abnormal glucose tolerance in all women with PCOS. The approach to detection of glucose intolerance among women with PCOS varies among health care providers. Large prospective studies are still needed for the development of guidelines with strong evidence. When assessing risk of future diabetes in women with PCOS, it is important to take into account the method used for screening as well as other risk factors that these women might have.

Citing Articles

Characteristics and risk factors associated with developing prediabetes in Saudi Arabia.

Tourkmani A, Alharbi T, Bin Rsheed A, Alotaibi A, AlEisaa M, Youzghadli I Ann Med. 2024; 56(1):2413922.

PMID: 39392033 PMC: 11486171. DOI: 10.1080/07853890.2024.2413922.

High Prevalence of Prediabetes and Associated Risk Factors in Urban Areas of Pontianak, Indonesia: A Cross-Sectional Study.

Budiastutik I, Kartasurya M, Subagio H, Widjanarko B J Obes. 2022; 2022:4851044.

PMID: 36536959 PMC: 9759381. DOI: 10.1155/2022/4851044.

Distribution of normal and pathological OGTTs among pregnant population and non-pregnant women with PCOS - the cross-sectional study.

Gojnic-Dugalic M, Stefanovic K, Stefanovic A, Jotic A, Lalic N, Petronijevic-Vrzic S Medicine (Baltimore). 2021; 100(37):e27232.

PMID: 34664864 PMC: 8448046. DOI: 10.1097/MD.0000000000027232.

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.

Ferjan S, Jensterle M, Oblak T, Zitnik I, Marc J, Goricar K J Int Med Res. 2019; 47(10):4691-4700.

PMID: 31438749 PMC: 6833370. DOI: 10.1177/0300060519865351.

Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome.

Xu X, Kou L, Wang H, Bo C, Song X Mol Med Rep. 2019; 19(3):2220-2230.

PMID: 30664204 PMC: 6390034. DOI: 10.3892/mmr.2019.9872.

References

Diamanti-Kandarakis E, Dunaif A . Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6):981-1030. PMC: 5393155. DOI: 10.1210/er.2011-1034. View

Glintborg D, Hojlund K, Andersen N, Hansen B, Beck-Nielsen H, Wojtaszewski J . Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab. 2008; 93(9):3618-26. DOI: 10.1210/jc.2008-0760. View

Meyer C, McGrath B, Teede H . Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007; 30(3):471-8. DOI: 10.2337/dc06-0618. View

Godoy-Matos A, Vaisman F, Pedrosa A, Farias M, Mendonca L, Pinheiro M . Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25(12):793-8. DOI: 10.3109/09513590903015528. View

Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I . Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006; 21(6):1426-31. DOI: 10.1093/humrep/del003. View

Yildirim B, Sabir N, Kaleli B . Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003; 79(6):1358-64. DOI: 10.1016/s0015-0282(03)00265-6. View

Sarray S, Madan S, Saleh L, Mahmoud N, Almawi W . Validity of adiponectin-to-leptin and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome. Fertil Steril. 2015; 104(2):460-6. DOI: 10.1016/j.fertnstert.2015.05.007. View

Yildiz B, Knochenhauer E, Azziz R . Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 93(1):162-8. PMC: 2190739. DOI: 10.1210/jc.2007-1834. View

Pierce G, Zhu H, Darracott K, Edet I, Bhagatwala J, Huang Y . Arterial stiffness and pulse-pressure amplification in overweight/obese African-American adolescents: relation with higher systolic and pulse pressure. Am J Hypertens. 2013; 26(1):20-6. PMC: 3626033. DOI: 10.1093/ajh/hps014. View

10.

Palmert M, Gordon C, Kartashov A, Legro R, Emans S, Dunaif A . Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87(3):1017-23. DOI: 10.1210/jcem.87.3.8305. View

11.

Norman R, Masters L, Milner C, Wang J, Davies M . Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001; 16(9):1995-8. DOI: 10.1093/humrep/16.9.1995. View

12.

Mani H, Levy M, Davies M, Morris D, Gray L, Bankart J . Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf). 2012; 78(6):926-34. DOI: 10.1111/cen.12068. View

13.

Salley K, Wickham E, Cheang K, Essah P, Karjane N, Nestler J . Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007; 92(12):4546-56. DOI: 10.1210/jc.2007-1549. View

14.

Hurd W, Abdel-Rahman M, Ismail S, Abdellah M, Schmotzer C, Sood A . Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril. 2011; 96(4):1043-7. DOI: 10.1016/j.fertnstert.2011.07.002. View

15.

Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G . Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2010; 96(2):E304-11. DOI: 10.1210/jc.2010-1290. View

16.

Arslanian S, Lewy V, Danadian K . Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001; 86(1):66-71. DOI: 10.1210/jcem.86.1.7123. View

17.

Stovall D, Bailey A, Pastore L . Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt). 2011; 20(1):37-43. PMC: 3026650. DOI: 10.1089/jwh.2010.2053. View

18.

Legro R, Kunselman A, Dodson W, Dunaif A . Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1):165-9. DOI: 10.1210/jcem.84.1.5393. View

19.

Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen J . Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003; 88(1):148-56. DOI: 10.1210/jc.2002-020997. View

20.

Dunaif A, Finegood D . Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996; 81(3):942-7. DOI: 10.1210/jcem.81.3.8772555. View